Table 1.
Clinical profile of the 10 patients with LG-EESS
| Parameter | Number | Percent (%) |
|---|---|---|
| Age at diagnosis (median, range), year | 44.5 | 33–66 |
| Initial clinical presentation | ||
| Vaginal bleeding | 2 | 20 |
| Abd distention | 3 | 30 |
| Abd pain | 2 | 20 |
| Pruritus vulvae | 1 | 10 |
| Dysmenorrhea | 1 | 10 |
| None | 1 | 10 |
| History of gynecologic surgery | ||
| TAH for leiomyoma | 4 | 40% |
| CA125 (median, range), U/ml | 49.5 | 15.4–168.0 |
| Site of tumor | ||
| Vaginal wall | 2 | 20 |
| Sigmoid | 3 | 30 |
| Right ovary | 3 | 30 |
| Vulva | 1 | 10 |
| Pelvis | 1 | 10 |
| Initial surgery | ||
| Optimal tumor resection (R0 resection) | 5 | 50% |
| LND | 4 | 40 |
| Stage | ||
| I | 0 | 0 |
| II | 2 | 20 |
| III | 5 | 50 |
| IIII | 3 | 30 |
| Adjuvant treatment | ||
| QT | 2 | 20 |
| HT | 3 | 30 |
| QT+RT | 2 | 20 |
| QT+HT | 3 | 30 |
| Follow up (median, range), month | 94 | 27–228 |
| Relapse | 3 | 30 |
| Current status | ||
| AWD | 3 | 30 |
| NED | 7 | 70 |
RT Radiotherapy, QT Chemotherapy, HT Hormone therapy, AWD Alive with disease, NED No evidence of disease